Patent: 9,938,273
✉ Email this page to a colleague
Summary for Patent: 9,938,273
Title: | Compounds and methods for kinase modulation, and indications therefor |
Abstract: | Disclosed are compounds of Formula I: ##STR00001## or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z.sup.2, Z.sup.3, and Z.sup.5 are as described herein, compositions thereof, and uses thereof. |
Inventor(s): | Wu; Guoxian (Foster City, CA), Wu; Jeffrey (Berkeley, CA), Chan; Katrina (Fremont, CA), Dong; Ken (Berkeley, CA), Ewing; Todd (Walnut Creek, CA), Ibrahim; Prabha N. (Mountain View, CA), Lin; Jack (Hercules, CA), Spevak; Wayne (Berkeley, CA), Zhang; Ying (Fremont, CA) |
Assignee: | Plexxikon Inc. (Berkeley, CA) |
Application Number: | 15/370,631 |
Patent Claims: | see list of patent claims |
Details for Patent 9,938,273
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2035-12-07 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-12-07 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-12-07 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-12-07 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2035-12-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |